ArticleTranslational research : the journal of laboratory and clinical medicine2013
Current status of gene therapy for brain tumors.
Article in Translational research : the journal of laboratory and clinical medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 63 citations in OpenAlex.
- Erasable serum markers.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Nano-Based Technology in Glioblastoma.Molecules (Basel, Switzerland) · 2025Review
- Review
- Applications of polymeric nanoparticles in drug delivery for glioblastoma.Frontiers in pharmacology · 2024Review
- Oncolytic virus-based suicide gene therapy for cancer treatment: a perspective of the clinical trials conducted at Henry Ford Health.Translational medicine communications · 2023Review
- Systematic Review of Pediatric Brain Tumors in Neurofibromatosis Type 1: Status of Gene Therapy.Cureus · 2022Review
- Mesenchymal stromal cells as carriers of IL-12 reduce primary and metastatic tumors of murine melanoma.Scientific reports · 2021Article
- Current Approaches for Glioma Gene Therapy and Virotherapy.Frontiers in molecular neuroscience · 2021Review
- Extracellular Vesicles as Drug Delivery Vehicles to the Central Nervous System.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020Review
- Gene therapies for high-grade gliomas: from the bench to the bedside.Acta bio-medica : Atenei Parmensis · 2020Review
- Viral vector: potential therapeutic for glioblastoma multiforme.Cancer gene therapy · 2020Review
- MicroRNA-129 Inhibits Glioma Cell Growth by Targeting CDK4, CDK6, and MDM2.Molecular therapy. Nucleic acids · 2020Article
- miR-25-3p promotes glioma cell proliferation and migration by targeting FBXW7 and DKK3.Experimental and therapeutic medicine · 2019Article
- Widespread gene transfer to malignant gliomas with In vitro-to-In vivo correlation.Journal of controlled release : official journal of the Controlled Release Society · 2019Article
- Article
- Nanotheranostics: Emerging Strategies for Early Diagnosis and Therapy of Brain Cancer.Nanotheranostics · 2018Review
- Survivin a radiogenetic promoter for glioblastoma viral gene therapy independently from CArG motifs.Clinical and translational medicine · 2017Article
- Optogenetics and its application in neural degeneration and regeneration.Neural regeneration research · 2017Review
- Quantification of cellular and nuclear uptake rates of polymeric gene delivery nanoparticles and DNA plasmids via flow cytometry.Acta biomaterialia · 2016Article
- Transient fasting enhances replication of oncolytic herpes simplex virus in glioblastoma.American journal of cancer research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Glioblastoma (GBM) is the most common and deadliest primary brain tumor in adults, with current treatments having limited impact on disease progression. Therefore the development of alternative treatment options is greatly needed. Gene therapy is a treatment strategy that relies on the delivery of genetic material, usually transgenes or viruses, into cells for therapeutic purposes, and has been applied to GBM with increasing promise. We have included selectively replication-competent oncolytic viruses within this strategy, although the virus acts directly as a complex biologic anti-tumor agent rather than as a classic gene delivery vehicle. GBM is a good candidate for gene therapy because tumors remain locally within the brain and only rarely metastasize to other tissues; the majority of cells in the brain are post-mitotic, which allows for specific targeting of dividing tumor cells; and tumors can often be accessed neurosurgically for administration of therapy. Delivery vehicles used for brain tumors include nonreplicating viral vectors, normal adult stem/progenitor cells, and oncolytic viruses. The therapeutic transgenes or viruses are typically cytotoxic or express prodrug activating suicide genes to kill glioma cells, immunostimulatory to induce or amplify anti-tumor immune responses, and/or modify the tumor microenvironment such as blocking angiogenesis. This review describes current preclinical and clinical gene therapy strategies for the treatment of glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.